Michael Gordon, ICEID 2022: Oral sabizabulin reduces mortality in hospitalized patients with COVID-19 at high risk for acute respiratory distress syndrome
Sabizabulin is a microtubule disruptor initially developed as an anti-cancer agent that is being repurposed to treat COVID-19. The VERU-111 clinical trial (NCT04842747), which investigates the use of oral sabizabulin on hospitalized patients with COVID-19, is discussed in this touchRESPIRATORY interview with Dr Michael Gordon (HonorHealth Research Institute).Â
‘Oral sabizabulin reduces mortality in hospitalized patients with COVID-19 at high risk for acute respiratory distress syndrome’ was presented at the annual International Conference on Emerging Infectious Diseases (ICEID), August 7–10, 2022.
- What is sabizabulin and what is the rationale for its use in the treatment of COVID-19? (00:21)
- What were the aims, design and eligibility criteria of the VERU-111 clinical trial? (02:05)
- What were the primary and secondary endpoints, and how well were they achieved? (04:38)
- What was the safety profile of sabizabulin? (06:57)
- What were the limitations of the study and what further studies are needed? (08:06)
Disclosures: Michael Gordon is a consultant for OnQuality, Viracta, Qualigen, Leaderboard and MorphicTx; he receives grant/research support from Veru, FujiFilm, ATEA, Beigene, Incyte, Kinevant, Redhill and Syndax; he is on the Advisory Board for Pfizer.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Marianna Mignani.Â
Filmed as a highlight of ICEID 2022
